Intellia Therapeutics, Inc.
NASDAQ: NTLA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Leonard
- Employees
- 403
- Headquarters
- Cambridge, United States
- IPO year
- 2016
- Market cap
- $1.7B
- Website
- https://www.intelliatx.com
Loading NTLA…
Loading profile data…Frequently asked questions about NTLA
What does Intellia Therapeutics, Inc. (NTLA) do?
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hered...
Where does NTLA trade?
Intellia Therapeutics, Inc. (NTLA) trades on the NASDAQ Global Market.
What sector is NTLA in?
Intellia Therapeutics, Inc. (NTLA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Intellia Therapeutics, Inc.?
John Leonard is the chief executive officer of Intellia Therapeutics, Inc. (NTLA).
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc. is headquartered in United States.
Does NTLA pay a dividend?
Intellia Therapeutics, Inc. (NTLA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NTLA go public?
Intellia Therapeutics, Inc. (NTLA) completed its initial public offering in 2016.